Spackman, D. Eldon; Veenstra, David L. - In: PharmacoEconomics 26 (2008) 11, pp. 937-949
Background: A variety of pharmaceuticals are currently approved for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), but their relative economic value is unclear. The goal of this analysis was to compare the cost effectiveness of adefovir, entecavir, lamivudine,...